Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms Journal Article
| Authors: | Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; Diamond, E. L. |
| Article Title: | Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms |
| Abstract: | Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB-approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interrupted after achieving complete or partial response by 18-fluorodeoxyglucose positron emission tomography (FDG-PET). 17/22 (77%) of patients experienced disease relapse following treatment interruption. Achieving a complete response prior to interruption, having a mutation other than BRAFV600E, and receiving MEK inhibition only were each associated with a statistically significant improvement in relapse-free survival. Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment. © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. |
| Keywords: | mitogen activated protein kinase; adult; clinical article; treatment outcome; treatment response; aged; middle aged; gene mutation; genetics; myeloproliferative disorder; cancer recurrence; drug withdrawal; patient selection; treatment duration; unspecified side effect; cytarabine; methotrexate; positron emission tomography; follow up; neoplasm; neoplasms; gene targeting; enzyme inhibition; protein kinase inhibitor; recurrence; retrospective study; protein kinase inhibitors; health insurance; statistical significance; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; recurrent disease; patient decision making; targeted therapy; histiocytosis; drug substitution; b raf kinase; mitogen activated protein kinase kinase; mitogen-activated protein kinase kinases; proto-oncogene proteins b-raf; cladribine; recurrence free survival; langerhans cell histiocytosis; b raf kinase inhibitor; molecularly targeted therapy; mapk pathway; mitogen activated protein kinase kinase inhibitor; humans; human; male; female; article; sinus histiocytosis; erdheim chester disease; treatment interruption |
| Journal Title: | British Journal of Haematology |
| Volume: | 203 |
| Issue: | 3 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2023-11-01 |
| Start Page: | 389 |
| End Page: | 394 |
| Language: | English |
| DOI: | 10.1111/bjh.18964 |
| PUBMED: | 37400251 |
| PROVIDER: | scopus |
| PMCID: | PMC10615682 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work